Skip to site menu Skip to page content

Phase I Study: Bromodomain Inhibitor OTX015 in Patients with Acute Leukaemia

By Oncology Therapeutic Development (OTD)
Bromodomain and extra-terminal (BET) proteins are chromatin readers that preferentially affect the transcription of genes with super-enhancers, including oncogenes. BET proteins bind acetylated histone tails via their bromodomain, bringing the elongation complex to the promoter region. OTX015 specifically binds to BRD2, BRD3 and BRD4 to prevent BET proteins from binding to chromatin, inhibiting gene transcription. OTX015 inhibits proliferation in many haematological malignancy cell lines and patient cells, in vitro and in vivo. OTD Therapeutic Development aimed to establish the recommended dose of OTX-15 in patients with haematological malignancies. Download this report to find out the results of patients with acute leukaemia, including study methods, findings and interpretation.
Enter your details below to view the free white paper

By downloading this whitepaper, you acknowledge that GlobalData may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Related Content